Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis

This is a prospective, multi-center, open-access, single-arm trial to observe the real-world clinical efficacy of drug-eluting vertebral artery stenting system treatment for Atherosclerotic Vertebral Arteries Stenosis. Patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 1 year within 3 years.

Inclusion Criteria:Age ≥ 18 years old, gender is not limited;Patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems;Patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form.Exclusion Criteria:Unable to receive dual antiplatelet therapy due to known disease, or severe coagulation abnormalities, severe infections that are not controlled, severe systemic disease, uncontrollable hypertension, and contraindicated for surgery;With an aneurysm that cannot be treated earlier or simultaneously or is not suitable for surgery;Gastrointestinal disease with active bleeding;Previous myocardial infarction or large-scale cerebral infarction within 2 weeks;Known contraindications to heparin, rapamycin, anesthesia, and contrast agents;Life expectancy less than 12 months;the investigator judged patients to be unsuitable for participation in this study.